Antiangiogenic Therapy Inhibits Venous Thrombus Resolution

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Arteriosclerosis, Thrombosis and Vascular Biology

• Publication date

  2014-03-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1161/ATVBAHA.113.302998PMID 24436367
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Magnetic Resonance T1 Relaxation Time of Venous Thrombus Is Determined by Iron Processing and Predicts Susceptibility to Lysis

  2013cited by this paper
• Hypoxia and hypoxia-inducible factor 1 in venous thrombosis

  2013cited by this paper
• Role of Endogenous Vascular Endothelial Growth Factor in Endothelium-Dependent Vasodilation in Humans

  2013cited by this paper
• Phase I trial of axitinib combined with platinum doublets in patients with advanced non-small cell lung cancer and other solid tumours

  2012cited by this paper
• Loss of fibroblast HIF-1α accelerates tumorigenesis.

  2012cited by this paper
• Phase I study of axitinib combined with paclitaxel, docetaxel or capecitabine in patients with advanced solid tumours

  2012cited by this paper
• Endothelial Cell HIF-1α and HIF-2α Differentially Regulate Metastatic Success

  2012cited by this paper
• Adenoviral delivery of constitutively active HIF1alpha into venous thrombus.

  2012cited by this paper
• Protein fragments from the VEGF binding domain of fibronectin are expressed in distinct spatial and temporal patterns during venous thrombus resolution.

  2012cited by this paper
• HIF-mediated endothelial response during cancer progression

  2012cited by this paper
• HIF1 signalling regulates venous thrombus resolution.

  2012cited by this paper
• Opinions on mouse models of thrombosis.

  2012cited by this paper
• Multicenter, Phase II Study of Axitinib, a Selective Second-Generation Inhibitor of Vascular Endothelial Growth Factor Receptors 1, 2, and 3, in Patients with Metastatic Melanoma

  2011cited by this paper
• The selective VEGFR1‐3 inhibitor axitinib (AG‐013736) shows antitumor activity in human neuroblastoma xenografts

  2011cited by this paper
• Techniques of assessing hypoxia at the bench and bedside

  2011cited by this paper
• Upregulation of hypoxia-inducible factor 1 alpha in local vein wall is associated with enhanced venous thrombus resolution

  2011cited by this paper
• Hypoxia and Upregulation of Hypoxia-Inducible Factor 1 alpha Stimulate Venous Thrombus Recanalization (vol 30, pg 2443, 2010)

  2011influential reference
• Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial.

  2011influential reference
• Venous valvular stasis-associated hypoxia and thrombosis: what is the link?

  2011cited by this paper
• Leukocytes and the natural history of deep vein thrombosis: current concepts and future directions.

  2011cited by this paper
• Short-term resistance training with blood flow restriction enhances microvascular filtration capacity of human calf muscles

  2010cited by this paper
• Integrative Physiology/Experimental Medicine Hypoxia and Upregulation of Hypoxia-Inducible Factor 1 Stimulate Venous Thrombus Recanalization

  2010cited by this paper
• Thrombotic events in patients with cancer receiving antiangiogenesis agents.

  2009cited by this paper
• Cellular source and amount of vascular endothelial growth factor and platelet-derived growth factor in tumors determine response to angiogenesis inhibitors.

  2009cited by this paper
• Dominant Effect of Antiangiogenesis in Combination Therapy Involving Cyclophosphamide and Axitinib

  2009cited by this paper
• Potential vascular actions of 2-methoxyestradiol.

  2009cited by this paper
• Adenovirus-Mediated VEGF Gene Therapy Enhances Venous Thrombus Recanalization and Resolution

  2008cited by this paper
• Nonclinical Antiangiogenesis and Antitumor Activities of Axitinib (AG-013736), an Oral, Potent, and Selective Inhibitor of Vascular Endothelial Growth Factor Receptor Tyrosine Kinases 1, 2, 3

  2008cited by this paper
• Blocking VEGFR-3 suppresses angiogenic sprouting and vascular network formation

  2008cited by this paper
• Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis.

  2008cited by this paper
• HIF-1alpha inhibition ameliorates neonatal brain injury in a rat pup hypoxic-ischemic model.

  2008cited by this paper
• 2-methoxyestradiol inhibits hypoxia-inducible factor-1{alpha} and suppresses growth of lesions in a mouse model of endometriosis.

  2008cited by this paper
• Mechanisms of venous thrombosis and resolution.

  2008cited by this paper
• Efficacy of gemcitabine plus axitinib compared with gemcitabine alone in patients with advanced pancreatic cancer: an open-label randomised phase II study.

  2008cited by this paper
• Production of Type VI Collagen by Human Macrophages: A New Dimension in Macrophage Functional Heterogeneity1 2

  2008cited by this paper
• Proteomics Identifies Thymidine Phosphorylase As a Key Regulator of the Angiogenic Potential of Colony-Forming Units and Endothelial Progenitor Cell Cultures

  2008cited by this paper
• HIF-1 alpha inhibition ameliorates neonatal brain damage after hypoxic-ischemic injury.

  2008cited by this paper
• [Thromboembolic risk associated with use of angiogenesis inhibitors used for the treatment of cancers].

  2008cited by this paper
• Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy

  2007cited by this paper
• The Molecular Basis of VEGFR-1 Signal Transduction Pathways in Primary Human Monocytes

  2007cited by this paper
• 2-Methoxyestradiol reduces monocyte adhesion to aortic endothelial cells in ovariectomized rats.

  2007cited by this paper
• Effect of inhibition of vascular endothelial growth factor signaling on distribution of extravasated antibodies in tumors.

  2006cited by this paper
• Phase I clinical trial of oral 2-methoxyestradiol, an antiangiogenic and apoptotic agent, in patients with solid tumors

  2006cited by this paper
• Rapid vascular regrowth in tumors after reversal of VEGF inhibition.

  2006cited by this paper
• Monocyte recruitment in venous thrombus resolution.

  2006cited by this paper
• Targeted Deletion of CCR2 Impairs Deep Vein Thombosis Resolution in a Mouse Model12

  2006cited by this paper
• PTEN and hypoxia regulate tissue factor expression and plasma coagulation by glioblastoma.

  2005cited by this paper
• Vascular endothelial growth factor naked DNA gene transfer enhances thrombus recanalization and resolution.

  2005cited by this paper
• Deep vein thrombosis in cancer: the scale of the problem and approaches to management.

  2005cited by this paper
• Endothelial Progenitor Cells Are Recruited Into Resolving Venous Thrombi

  2005cited by this paper
• The role of neovascularisation in the resolution of venous thrombus

  2005cited by this paper
• 2-Methoxyestradiol: an Endogenous Antiangiogenic and Antiproliferative Drug Candidate

  2004influential reference
• Mechanism of monocyte activation and expression of proinflammatory cytochemokines by placenta growth factor.

  2003cited by this paper
• 2ME2 inhibits tumor growth and angiogenesis by disrupting microtubules and dysregulating HIF.

  2003cited by this paper
• Targeting HIF-1 for cancer therapy

  2003cited by this paper
• Role of blood mononuclear cells in recanalization and vascularization of thrombi: past, present, and future.

  2003cited by this paper
• Failure of Thrombus to Resolve in Urokinase-Type Plasminogen Activator Gene-Knockout Mice: Rescue by Normal Bone Marrow-Derived Cells

  2003cited by this paper
• HIF-1alpha is essential for myeloid cell-mediated inflammation.

  2003cited by this paper
• Vascular endothelial growth factor enhances venous thrombus recanalisation and organisation

  2003cited by this paper
• HIF-1 Is Essential for Myeloid Cell-Mediated

  2003cited by this paper
• Quality-of-life improvement using thrombolytic therapy for iliofemoral deep venous thrombosis.

  2002cited by this paper
• Antithrombotic effects of controlled inhibition of factor VIII with a partially inhibitory human monoclonal antibody in a murine vena cava thrombosis model.

  2002cited by this paper
• Vascular endothelial growth factor-A-induced chemotaxis of monocytes is attenuated in patients with diabetes mellitus: A potential predictor for the individual capacity to develop collaterals.

  2000cited by this paper
• Vascular endothelial growth factor and basic fibroblast growth factor are found in resolving venous thrombi.

  2000cited by this paper
• Hypoxia/Hypoxemia-Induced activation of the procoagulant pathways and the pathogenesis of ischemia-associated thrombosis.

  1999cited by this paper
• Determinants of chronic venous disease after acute deep venous thrombosis.

  1998cited by this paper
• 2-Methoxyestradiol, an endogenous estrogen metabolite, induces apoptosis in endothelial cells and inhibits angiogenesis: possible role for stress-activated protein kinase signaling pathway and Fas expression.

  1997cited by this paper
• Hypoxia-induced modulation of endothelial cell properties: regulation of barrier function and expression of interleukin-6.

  1997cited by this paper
• The Vascular Endothelial Growth Factor Receptor Flt-1 Mediates Biological Activities

  1996cited by this paper
• The endogenous oestrogen metabolite 2-methoxyoestradiol inhibits angiogenesis and suppresses tumour growth

  1994cited by this paper
• The PO2 in venous valve pockets: Its possible bearing on thrombogenesis

  1981cited by this paper

• Antithrombotic Therapy on Antithrombin Resistance in a Mouse Model.

  2026cites this paper
• The Role of the Pulmonary Vascular Microenvironment in Chronic Thromboembolic Pulmonary Hypertension

  2025cites this paper
• Distinct endothelial cells in chronic thromboembolic pulmonary hypertension

  2025cites this paper
• Monocyte/macrophage-mediated venous thrombus resolution

  2024cites this paper
• Platelet-based bioactive systems guided precision targeting and immune regulation for cancer therapy

  2024cites this paper
• Integrating network pharmacology with microRNA microarray analysis to identify the role of miRNAs in thrombosis treated by the Dahuang Zhechong pill

  2024cites this paper
• Endothelial Features Along the Pulmonary Vascular Tree in Chronic Thromboembolic Pulmonary Hypertension: Distinctive or Shared Facets?

  2024cites this paper
• Angiogenesis in Chronic Thromboembolic Pulmonary Hypertension: A Janus-Faced Player?

  2024cites this paper
• Circulating miR-let7a levels predict future diagnosis of chronic thromboembolic pulmonary hypertension

  2024cites this paper
• Molecular Pathophysiology of Chronic Thromboembolic Pulmonary Hypertension: A Clinical Update from a Basic Research Perspective

  2024cites this paper
• Overview of Venous Thromboembolism and Emerging Therapeutic Technologies Based on Nanocarriers-Mediated Drug Delivery Systems

  2024cites this paper
• Experimental venous thrombus resolution is driven by IL-6 mediated monocyte actions

  2023cites this paper
• Endothelial Overexpression of TGF-β-Induced Protein Impairs Venous Thrombus Resolution

  2023cites this paper
• Impairment of Angiogenesis-Driven Clot Resolution Is a Key Event in the Progression to Chronic Thromboembolic Pulmonary Hypertension: Validation in a Novel Rabbit Model

  2023cites this paper
• Low molecular weight heparin synergistically enhances the efficacy of adoptive and anti-PD-1-based immunotherapy by increasing lymphocyte infiltration in colorectal cancer

  2023cites this paper
• Pulmonary Thrombosis Promotes Tumorigenesis via Myeloid Hypoxia-Inducible Factors

  2022cites this paper
• Hypoxia and hypoxia‐inducible factors promote the development of neointimal hyperplasia in arteriovenous fistula

  2021cites this paper
• Chronic Thromboembolic Pulmonary Hypertension: the Bench

  2021cites this paper
• Cardiovascular toxicity of angiogenesis inhibitors and immune checkpoint inhibitors: synergistic anti-tumour effects at the cost of increased cardiovascular risk?

  2021cites this paper
• Role of angiopoietin-2 in venous thrombus resolution and chronic thromboembolic disease

  2021cites this paper
• Cancer Therapy–Associated Thrombosis

  2021cites this paper
• Surviving and thriving in thrombosis research during a global pandemic: Experiences of a vascular scientist diagnosed with COVID-19

  2020cites this paper
• By word of mouse: using animal models in venous thrombosis research

  2020cites this paper
• Reactive Oxygen Species in Venous Thrombosis

  2020cites this paper
• AKT2 regulates endothelial-mediated coagulation homeostasis and promotes intrathrombotic recanalization and thrombus resolution in a mouse model of venous thrombosis

  2020cites this paper
• Activated Endothelial TGFβ1 Signaling Promotes Venous Thrombus Non-Resolution in Mice Via Endothelin-1: Potential Role for Chronic Thromboembolic Pulmonary Hypertension.

  2019cites this paper
• Pro-inflammatory chemokine interleukin-17A may increase venous thrombus resolution by increasing venous thrombus neovascularization

  2019cites this paper
• Potential Involvement of Osteopontin in Inflammatory and Fibrotic Processes in Pulmonary Embolism and Chronic Thromboembolic Pulmonary Hypertension

  2019cites this paper
• The stimulation of thrombosis by hypoxia.

  2019cites this paper
• Choosing a mouse model of venous thrombosis: a consensus assessment of utility and application

  2019cites this paper
• Choosing a Mouse Model of Venous Thrombosis.

  2019cites this paper
• Thrombotic risk factors in patients with superior vena cava syndrome undergoing chemotherapy via femoral inserted central catheter.

  2019cites this paper
• Inhibition of prolyl hydroxylase domain proteins selectively enhances venous thrombus neovascularisation.

  2018cites this paper
• Role of Endothelial Cells in Acute and Chronic Thrombosis

  2018cites this paper
• Sepsis-induced thrombus formation and cell-specific HIFs.

  2018cites this paper
• Chapter 28 – Overview

  2017cites this paper
• Hypoxia inducible factor as a therapeutic target for atherosclerosis.

  2017cites this paper
• Current understanding of the pathophysiology of chronic thromboembolic pulmonary hypertension.

  2017cites this paper
• Modelling pulmonary microthrombosis coupled to metastasis: distinct effects of thrombogenesis on tumorigenesis

  2017cites this paper
• Thrombus leukocytes exhibit more endothelial cell-specific angiogenic markers than peripheral blood leukocytes do in acute coronary syndrome patients, suggesting a possibility of trans-differentiation: a comprehensive database mining study

  2017cites this paper
• Impact of thrombosis on pulmonary endothelial injury and repair following sepsis.

  2017cites this paper
• From thrombosis to fibrosis in chronic thromboembolic pulmonary hypertension

  2017cites this paper
• Chapter 18 – Axitinib

  2017cites this paper
• Involvement of inflammatory markers in pathogenesis of venous thromboembolism

  2017cites this paper
• Advances in our understanding of mechanisms of venous thrombus resolution

  2016cites this paper
• Diverse roles of cell-specific hypoxia-inducible factor 1 in cancer-associated hypercoagulation.

  2016cites this paper
• Inducing femoral vein thrombosis under unrestricted flow: Comments on an alternative electrolytic mouse model.

  2016cites this paper
• High rates of venous thromboembolic events in patients undergoing systemic therapy for urothelial carcinoma: A systematic review and meta-analysis.

  2016cites this paper
• Assessment of Venous Thrombosis in Animal Models

  2016cites this paper
• Cancer-Associated Thrombosis: Regulatory Mechanisms and Emerging Directions.

  2016cites this paper
• THROMBOSIS AND HEMOSTASIS Diverse roles of cell-speci fi c hypoxia-inducible factor 1 in cancer-associated hypercoagulation

  2016cites this paper
• Bevacizumab promotes venous thromboembolism through the induction of PAI-1 in a mouse xenograft model of human lung carcinoma

  2015cites this paper
• Swine Model of Thrombotic Caval Occlusion Created by Autologous Thrombus Injection with Assistance of Intra-caval Net Knitting

  2015cites this paper
• Quantification of experimental venous thrombus resolution by longitudinal nanogold-enhanced micro-computed tomography

  2015cites this paper
• Approach to chemotherapy-associated thrombosis

  2015cites this paper
• Suppression of erythropoiesis by dietary nitrate

  2014cites this paper
• Local accumulation of hypoxia-inducible factor 2 alpha during venous thrombus resolution.

  2014cites this paper
• Suppression of angiogenic response in local vein wall is associated with reduced thrombus resolution.

  2014cites this paper